A Controlled Study of Survival With Dementia

Martin, David C.; Miller, Judson K.; Kapoor, Wishwa N.; Arena, Vincent C.; Boller, François

doi:10.1001/archneur.1987.00520230012006

Cited by 75 publications

(56 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using these methods the MMSE profile of a treated and untreated patient group are presented, as per Table 51. The model also included a mortality rate of 5.77% per 6-month cycle (based on a study by Martin and colleagues 129 ).…”

Section: Industry Submission On Costeffectiveness Of Rivastigminementioning

confidence: 99%

“…112,129,171 Studies have taken different approaches to assessing the impact that AD has on life span; some report a hazard ratio for the increased risk of death for AD patients in comparison with the mortality risk in the general population, whereas others have developed models to try to predict the expected survival time for a person with AD.…”

Section: Mortality and Admentioning

confidence: 99%

“…Martin and colleagues 129 report data on mortality in a sample of patients with dementia compared with controls matched by sex and age who did not have dementia. Patients were followed up between 1981 and 1986 (mean follow-up 36.5 months); the survival of patients with dementia at 3 years was 70% versus 84% in controls ( p < 0.001).…”

Section: Mortality and Admentioning

confidence: 99%

“…Although it is accepted that there may be differences in mortality by age (as shown by Burns and colleagues 172 ) and severity, the data do not allow us to differentiate by these groups at present. An annual mortality rate of 11.2% is applied in the model (using a monthly rate in each cycle), using data from Martin and colleagues, 129 who report a mortality rate of 30% over 3 years. Sensitivity analysis on the mortality rate used is undertaken/reported.…”

Section: Mortality Datamentioning

confidence: 99%

See 3 more Smart Citations

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease

Loveman

Green²,

Kirby³

et al. 2006

Health Technol Assess

165

114

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTAThe clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care.The HTA Programme commissions research only on topics where it has identified key ...

show abstract

Section: Industry Submission On Costeffectiveness Of Rivastigminementioning

confidence: 99%

Section: Mortality and Admentioning

confidence: 99%

Section: Mortality and Admentioning

confidence: 99%

Section: Mortality Datamentioning

confidence: 99%

See 2 more Smart Citations

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease

Loveman

Green²,

Kirby³

et al. 2006

Health Technol Assess

165

114

View full text Add to dashboard Cite

show abstract

“…There are suggestions that Alzheimer's disease brings death forwards less than multi-infarct dementia, but the picture is variable (Martin et al, 1987). Misidentification syndrome is associated with longer life among patients with Alzheimer's disease in contact with psychiatric services (Burns et al, 1991).…”

Section: Dementia Spectrum Diagnosismentioning

confidence: 99%